Oligon Therapeutics builds next‑generation RNAi medicines using its proprietary SeekR platform, which fuses two RNA aptamer binders with two siRNA silencers into a single self‑delivering drug. The dual binders cross‑link cell‑surface receptors, achieving up to ten‑fold higher internalization and enabling precise delivery to any cell subtype, including T‑cells and cancer cells. Once inside the target cell, the released siRNAs trigger multi‑targeted gene silencing to reprogram cellular programs for therapeutic effect.
Funding
Funding not disclosed
Founders
Product
Problem
Current RNAi therapeutics rely on delivery vehicles such as lipid nanoparticles or conjugates that often exhibit limited cell-type specificity, low internalization efficiency, and require complex formulation processes. These constraints hinder the ability to precisely reprogram target cells, especially hard-to-transfect populations like T‑cells and certain cancer cells.
Solution
Oligon Therapeutics’ proprietary SeekR platform creates a single, self‑delivering injectable drug that combines two RNA aptamer binders with two siRNA silencers. The dual aptamers cross‑link two cell‑surface receptors, generating a high‑avidity interaction that triggers receptor‑mediated endocytosis and achieves up to ten‑fold higher internalization compared with conventional RNAi carriers. Once inside the target cell, the embedded siRNAs execute multi‑targeted RNA interference, enabling precise modulation of cellular programs without the need for external formulation or delivery excipients. The modular architecture allows rapid re‑engineering of both the binders and siRNA payloads to address diverse disease indications across any cell subtype.
Target Audience
Primary customers are biopharmaceutical companies and research institutions developing RNAi‑based therapies that require precise, efficient delivery to specific cell populations, including immuno‑oncology and cell‑reprogramming programs.
Features
- Bivalent RNA aptamer binders that selectively cross‑link two surface receptors for high‑avidity, receptor‑mediated uptake
- Integrated dual siRNA payload delivering simultaneous knockdown of two genes for multi‑targeted therapeutic control
- Self‑delivering injectable format requiring no lipid nanoparticles, polymers, or other formulation components
- Modular design enabling rapid substitution of aptamer and siRNA sequences to target new cell types or disease pathways
- AI‑driven molecular modeling pipeline that accelerates discovery and optimization of aptamer‑receptor interactions
- Demonstrated ten‑fold increase in cellular internalization efficiency in hard‑to‑transfect cells such as T‑cells and cancer cells